



European College of
Neuropsychopharmacology

Annual Report 2023



European College of Neuropsychopharmacology

Annual Report 2023

1. About ECNP	3
Objectives	3
Executive Committee	3
2. Activities 2023	5
Promoting and disseminating science	5
Fostering talent	6
Public outreach	6
3. Financial Overview	7
Financial statements	7
4. Future Outlook	9



The European College of Neuropsychopharmacology is a public-interest-serving entity (*algemeen nut beogende instelling* – ANBI) under Dutch tax law.

1. About ECNP

Objectives

ECNP is an independent European scientific association that exists to promote high-quality experimental and clinical research in applied and translational neuroscience with a view to stimulating the development of better treatments for those suffering from disorders of the brain.

The mission of ECNP is to advance the science of the brain, promote better treatment and enhance brain health. It is non-profit-making.

Address: Daltonlaan 400, 3584 BK Utrecht

E-mail: secretariat@ecnp.eu

Website: <https://www.ecnp.eu>

RSIN: 823523974

Dutch TAX number: NL 823523974B01

ANBI: The European College of Neuropsychopharmacology is a public-interest-serving entity (*algemeen nut beogende instelling* – ANBI) under Dutch tax law.

The European College of Neuropsychopharmacology is referred to hereafter as 'ECNP' or 'the College'.

Executive Committee

Officers

Martien Kas
President
University of Groningen
The Netherlands

Andreas Reif
President-Elect
University Hospital Frankfurt
Germany

Elisabeth Binder
Vice-President
Max Planck Institute of Psychiatry
Munich, Germany

Suzanne Dickson
Secretary
University of Gothenburg
Sweden

Gitte Moos Knudsen
Past-President
Copenhagen University Hospital
Denmark

Brenda Penninx
Treasurer
Amsterdam University Medical Center
The Netherlands

Councillors

David Baldwin
University of Southampton
United Kingdom

Iiris Hovatta
University of Helsinki
Finland

Paolo Brambilla
University of Milan
Italy

Marin Jukić
University of Belgrade
Serbia

Iria Grande
Hospital Clinic de Barcelona
Spain

Marion Leboyer
University of Paris Est Créteil
France

Co-opt member

Gerry-Dawson
P1vital, Ltd
Wallingford, United Kingdom

Ex officio members

John Cryan
Chair, Scientific Programme Committee
35th, 36th, 37th ECNP Congress
University College Cork
Ireland

Eduard Vieta
Editor-in-Chief, *European
Neuropsychopharmacology*
University of Barcelona
Spain

Andreas Meyer-Lindenberg
Editor-in-Chief, *Neuroscience Applied*
Central Institute of Mental Health (ZI)
Mannheim, Germany

Executive Director

Alexander Schubert

The members of the Executive Committee receive no remuneration for their role. The President receives € 15,000 per annum, payable to his institution, for secretarial assistance. Each Officer receives € 4,000 per annum, payable to his or her institution, for secretarial assistance. And each member of the Executive Committee is entitled to € 1,500 per annum to cover associated meeting costs, including ground transportation, lunch, dinner, drinks, etc.

2. ECNP Activities 2023

To execute its mission to support European applied and translational neuroscience, ECNP performs a number of activities annually, focusing especially on stimulating research, sponsoring education and raising awareness.

Promoting and disseminating science

- **European Neuropsychopharmacology**

ECNP publishes, in partnership with Elsevier B.V., the international peer-reviewed journal *European Neuropsychopharmacology*, featuring the latest in applied brain science across the spectrum of basic and clinical and research. The 2023 impact factor is 5.600.

- **ECNP Networks and Thematic Working Groups (TWGs)**

These virtual, multi-centre European research clusters provide a unique platform for the collection and aggregation of continent-wide clinical data, in order to foster research collaboration and ideas-sharing across the translational neurosciences.

The 23 Networks and Thematic Working Groups collectively comprise one of ECNP's most far-reaching initiatives, bringing together several hundred of Europe's leading researchers in applied and translational neuroscience, and providing the springboard for some of the region's largest and most important projects in brain research.

- **The International Society for CNS Clinical Trials and Methodology (ISCTM)**

ISCTM is an independent organisation devoted to advancing clinical research methods related to the development and use of central nervous system (CNS) therapeutics. Every two years the ECNP-ISCTM joint meeting brings together international stakeholders in academia, industry, government, and the regulatory and payer communities to address strategic clinical, regulatory, methodological and policy challenges in CNS clinical research.

A joint meeting was held on 5-7 October in Barcelona, Spain.

- **ECNP Neuropsychopharmacology Award**

This award, conferred annually, recognises exceptional research achievements in applied and translational neuroscience, alternating between basic and clinical science. The award comes with a prize of € 10,000, contingent upon publication of a review paper in *European Neuropsychopharmacology*.

Winner 2023: Oscar Marín, United Kingdom (preclinical)

- **ECNP Citation Prize**

Awarded to the most-cited research paper in the ECNP journal, *European Neuropsychopharmacology* (ENP) in the preceding two years, the award recognises and encourages impactful original research. Promoted by ECNP.

Winner 2023: Kamilla Woznica Miskowiak et al., 'Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables', *Eur. Neuropsychopharmacol*, 46, 2021, 39-48.

Fostering talent

- **ECNP Early Career Academy**

The ECNP Early Career Academy (ECA) offers a range of benefits aimed at fostering connectivity between outstanding early career scientists, facilitating their sustained, career-long engagement in ECNP, and providing opportunities to amplify their contributions to applied neuroscience. Developed in 2023 for launch in 2024, the Academy will grow to 100 members over five years, with each member serving a five-year term.

- **ECNP Rising Star Award**

The ECNP Rising Star Award honours early career researchers in applied and translational neuroscience who have the potential to advance the science of treatment and prevention of brain disorders. Conferred for the first time in 2020, in 2021 the number of awards was doubled. The award comes with an unrestricted prize of € 2,000 for each winner.

Winners 2023: Liubov Kalinichenko, Germany, and Nils Opel, Germany.

- **ECNP Research Internship**

The ECNP Research Internship (ERI) offers 15 early career scientists the opportunity of a short two-week exploratory experience in another European country.

Public outreach

- **European Affairs**

ECNP collaborates with a number of European societies to build European research and clinical capacity and advance the interests of the neuroscience research and best-practices treatment in Europe.

- ALBA Network for diversity, equity and inclusion in neuroscience – supporter
- Biomedical Alliance in Europe – member
- European Brain Council (EBC) – founding member
- European Federation of Psychiatric Trainees (EFPT) – supporter
- Federation of European Neuroscience Societies (FENS) – founding member
- Expert Platform on Mental Health – Depression (EPD) – supporter
- Global Alliance of Mental Illness Advocacy Networks (GAMIAN-Europe) – member

3. Financial Overview

ECNP's policy is at all times to handle its disposable assets in a responsible and sustainable manner. The principles of this policy are:

- Proactive tax and regulatory compliance
- Strict observance of the requirements of ANBI ('algemeen nut beogende instelling' = public-interest-service entity) status
- Capital preservation – and adherence to agreed levels
- Budgetary discipline
- Ongoing diversification of the revenue base

To give substance to this, ECNP invests in securities through an established asset manager using a defensive policy. The goal is to preserve wealth, to ensure the College can continue to perform its public-good activities, not to maximise return.

Financial statements

Balance sheet as at 31 December 2023 (after appropriation of profit/losses)

	31-12-2023		31-12-2022	
	€	€	€	€
ASSETS				
FIXED ASSETS				
Financial fixed assets				
Securities		15,400,194		15,400,194
CURRENT ASSETS				
Accounts receivable				
Debtors	4,083		3,569	
Taxes	18,185		4,110	
Other accounts receivable	134,645		160,994	
		156,913		168,673
Bank deposits		30,272		589,368
		187,185		758,041
		<u>15,587,379</u>		<u>16,158,235</u>

	31-12-2023		31-12-2022	
	€	€	€	€
EQUITY AND LIABILITIES				
EQUITY				
Other reserves		15,374,453		15,974,934
CURRENT LIABILITIES				
Trade creditors	28,011		44,019	
Other liabilities	184,915		139,282	
		212,926		183,301
		<u>15,587,379</u>		<u>16,158,235</u>

Statement of income and expenditure 2023


	Balance 2023	Balance 2022
	€	€
Income		
Membership fees	118,884	93,570
Royalties	133,145	126,857
Interest and similar income	2,249	87,225
Total income	<u>254,278</u>	<u>307,652</u>
Expenses		
Administration	374,038	301,136
Other expenses	476,212	382,401
Total expenses	<u>850,250</u>	<u>683,537</u>
Balance before financial expense	<u>-595,972</u>	<u>-375,885</u>
Interest and similar charges	-4,509	-4,707
Net result	<u>-600,481</u>	<u>-380,592</u>
Appropriation of result		
Other reserves	<u>-600,481</u>	<u>-380,592</u>

4. Future Outlook

The process of reviewing ECNP's role in the ecosystem of European brain science and treatment research and updating the College's activities to meet the changing needs of the applied neuroscience community continues apace. As it has for organisations everywhere, the new reality has raised some fundamental questions about ECNP's future role and what adaptations will have to be made to maintain its relevance and ongoing viability. Formulating a response to these questions is the organisation's current strategic focus. Specific issues include:

- How the landscape of European brain science is changing and how ECNP's programmes and activities should adapt to accommodate these changes.
- How the organisation's activities can meet the scale of the need they are designed to serve and achieve an impact commensurate with the College's mission.
- Where the organisation should focus its (finite) energies and resources to make the most meaningful and lasting improvements to the field.
- How can the volunteer engagement on which the organisation depends be maintained.
- How the organisation can fulfil its social obligation to reduce its carbon footprint and contribute to environmental preservation.
- How the organisation's governance structures can be strengthened to manage the kind of changes likely to be necessary.

Plans are being developed to effect change and renewal in all of these areas and equip the organisation with the structures and systems necessary to meet the next 35 years of its existence.



© 2024 European College of Neuropsychopharmacology